Delivery Order SPE2DR25D1017-SPE2DR26F9BDT
Award Date 12/10/25
Potential Completion Date 12/11/25
Potential Value $9.5K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $6,558.40 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on November 25, 2025, with completion by November 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $10,969.97 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price delivery order was placed under no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid...
- The Defense Logistics Agency awarded a delivery order valued at $15,558.30 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on September 24, 2025, with completion scheduled for September 25, 2025. This firm fixed price, non-set-aside contract is performed at the awardee's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $10,130.76 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count unit of use packaging) on November 7, 2025, with completion targeted for November 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $5,137.84 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packaging) on October 17, 2025, with an ultimate completion date of October 20, 2025. This firm fixed-price, competitively awarded delivery order was issued without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $13,173.98 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units) under a firm fixed-price contract type. This non-set-aside competitive award was executed on December 1, 2025, with an ultimate completion date of December 2, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid...
- The Defense Logistics Agency awarded a delivery order valued at $9,147.03 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit of use packaging) on May 6, 2025, with an ultimate completion date of May 7, 2025. This firm fixed-price, non-set-aside contract was awarded competitively and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a $10,548.57 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit of use packaging) on July 28, 2025, with completion scheduled for July 29, 2025. This competitively awarded, firm fixed price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a delivery order valued at $10,437.46 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count bottles) on December 1, 2025, with an ultimate completion date of December 2, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $20,525.18 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on November 26, 2025, with an ultimate completion date of November 28, 2025. This non-set-aside, firm fixed-price delivery order is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions,...